 | • レポートコード：QFJ1-3592 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、127ページ • 納品方法：Eメール（納期：3日） • 産業分類：産業装置 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、個別化医療＆エピゲノミクスの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（試薬、キット、器具、酵素、サービス）、用途別市場規模（腫瘍、非腫瘍、癌治療薬）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・個別化医療＆エピゲノミクスの市場動向 ・企業の競争状況、市場シェア ・個別化医療＆エピゲノミクスの種類別市場規模と予測2016-2027（試薬、キット、器具、酵素、サービス） ・個別化医療＆エピゲノミクスの用途別市場規模と予測2016-2027（腫瘍、非腫瘍、癌治療薬） ・個別化医療＆エピゲノミクスの北米市場規模2016-2027（アメリカ、カナダ） ・個別化医療＆エピゲノミクスの欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・個別化医療＆エピゲノミクスのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・個別化医療＆エピゲノミクスの中南米市場規模2016-2027（メキシコ、ブラジル） ・個別化医療＆エピゲノミクスの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Abbott Laboratories、Affymetrix、Agilent Technologies、Astellas Pharmaceuticals、BAYER AG、Bio Vision、Celgene Corp.、Emd Millipore、Epigenomics AG、Epigentex、Envivo Pharmaceuticals (Forum Pharmaceutricals)、Gilead Sciences、Glaxosmithkline、Illumina Inc.、Johnson & Johnson、Karus Therapeutics Limited、Laboratory Corp. Of America Holdings、LES Laboratoires Servier、Merck、Naturewise Biotech & Medicals Corp.、Novartis Pharma AG、Oncolys Biopharma Inc.、Orchid Chemicals & Pharmaceuticals Limited、Progen Pharmaceuticals Limited、Quest Diagnostics、Roche Holding AG、Rubicon Genomics、Takeda Pharmaceutical Company Limited） ・結論 |
Market Analysis and Insights: Global Personalized Medicine and Epigenomics Market
The global Personalized Medicine and Epigenomics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Personalized Medicine and Epigenomics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Personalized Medicine and Epigenomics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Personalized Medicine and Epigenomics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Personalized Medicine and Epigenomics market.
Global Personalized Medicine and Epigenomics Scope and Market Size
Personalized Medicine and Epigenomics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Personalized Medicine and Epigenomics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Reagents
Kits
Instruments
Enzymes
Services
Segment by Application
Oncology
Non-Oncology
Cancer Drug Technology
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Abbott Laboratories
Affymetrix
Agilent Technologies
Astellas Pharmaceuticals
BAYER AG
Bio Vision
Celgene Corp.
Emd Millipore
Epigenomics AG
Epigentex
Envivo Pharmaceuticals (Forum Pharmaceutricals)
Gilead Sciences
Glaxosmithkline
Illumina Inc.
Johnson & Johnson
Karus Therapeutics Limited
Laboratory Corp. Of America Holdings
LES Laboratoires Servier
Merck
Naturewise Biotech & Medicals Corp.
Novartis Pharma AG
Oncolys Biopharma Inc.
Orchid Chemicals & Pharmaceuticals Limited
Progen Pharmaceuticals Limited
Quest Diagnostics
Roche Holding AG
Rubicon Genomics
Takeda Pharmaceutical Company Limited
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Personalized Medicine and Epigenomics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Reagents
1.2.3 Kits
1.2.4 Instruments
1.2.5 Enzymes
1.2.6 Services
1.3 Market by Application
1.3.1 Global Personalized Medicine and Epigenomics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Oncology
1.3.3 Non-Oncology
1.3.4 Cancer Drug Technology
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Personalized Medicine and Epigenomics Market Perspective (2016-2027)
2.2 Personalized Medicine and Epigenomics Growth Trends by Regions
2.2.1 Personalized Medicine and Epigenomics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Personalized Medicine and Epigenomics Historic Market Share by Regions (2016-2021)
2.2.3 Personalized Medicine and Epigenomics Forecasted Market Size by Regions (2022-2027)
2.3 Personalized Medicine and Epigenomics Industry Dynamic
2.3.1 Personalized Medicine and Epigenomics Market Trends
2.3.2 Personalized Medicine and Epigenomics Market Drivers
2.3.3 Personalized Medicine and Epigenomics Market Challenges
2.3.4 Personalized Medicine and Epigenomics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Personalized Medicine and Epigenomics Players by Revenue
3.1.1 Global Top Personalized Medicine and Epigenomics Players by Revenue (2016-2021)
3.1.2 Global Personalized Medicine and Epigenomics Revenue Market Share by Players (2016-2021)
3.2 Global Personalized Medicine and Epigenomics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Personalized Medicine and Epigenomics Revenue
3.4 Global Personalized Medicine and Epigenomics Market Concentration Ratio
3.4.1 Global Personalized Medicine and Epigenomics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Personalized Medicine and Epigenomics Revenue in 2020
3.5 Personalized Medicine and Epigenomics Key Players Head office and Area Served
3.6 Key Players Personalized Medicine and Epigenomics Product Solution and Service
3.7 Date of Enter into Personalized Medicine and Epigenomics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Personalized Medicine and Epigenomics Breakdown Data by Type
4.1 Global Personalized Medicine and Epigenomics Historic Market Size by Type (2016-2021)
4.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Type (2022-2027)
5 Personalized Medicine and Epigenomics Breakdown Data by Application
5.1 Global Personalized Medicine and Epigenomics Historic Market Size by Application (2016-2021)
5.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Personalized Medicine and Epigenomics Market Size (2016-2027)
6.2 North America Personalized Medicine and Epigenomics Market Size by Type
6.2.1 North America Personalized Medicine and Epigenomics Market Size by Type (2016-2021)
6.2.2 North America Personalized Medicine and Epigenomics Market Size by Type (2022-2027)
6.2.3 North America Personalized Medicine and Epigenomics Market Size by Type (2016-2027)
6.3 North America Personalized Medicine and Epigenomics Market Size by Application
6.3.1 North America Personalized Medicine and Epigenomics Market Size by Application (2016-2021)
6.3.2 North America Personalized Medicine and Epigenomics Market Size by Application (2022-2027)
6.3.3 North America Personalized Medicine and Epigenomics Market Size by Application (2016-2027)
6.4 North America Personalized Medicine and Epigenomics Market Size by Country
6.4.1 North America Personalized Medicine and Epigenomics Market Size by Country (2016-2021)
6.4.2 North America Personalized Medicine and Epigenomics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Personalized Medicine and Epigenomics Market Size (2016-2027)
7.2 Europe Personalized Medicine and Epigenomics Market Size by Type
7.2.1 Europe Personalized Medicine and Epigenomics Market Size by Type (2016-2021)
7.2.2 Europe Personalized Medicine and Epigenomics Market Size by Type (2022-2027)
7.2.3 Europe Personalized Medicine and Epigenomics Market Size by Type (2016-2027)
7.3 Europe Personalized Medicine and Epigenomics Market Size by Application
7.3.1 Europe Personalized Medicine and Epigenomics Market Size by Application (2016-2021)
7.3.2 Europe Personalized Medicine and Epigenomics Market Size by Application (2022-2027)
7.3.3 Europe Personalized Medicine and Epigenomics Market Size by Application (2016-2027)
7.4 Europe Personalized Medicine and Epigenomics Market Size by Country
7.4.1 Europe Personalized Medicine and Epigenomics Market Size by Country (2016-2021)
7.4.2 Europe Personalized Medicine and Epigenomics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Personalized Medicine and Epigenomics Market Size (2016-2027)
8.2 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Type
8.2.1 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Type (2016-2027)
8.3 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Application
8.3.1 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Application (2016-2027)
8.4 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region
8.4.1 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Personalized Medicine and Epigenomics Market Size (2016-2027)
9.2 Latin America Personalized Medicine and Epigenomics Market Size by Type
9.2.1 Latin America Personalized Medicine and Epigenomics Market Size by Type (2016-2021)
9.2.2 Latin America Personalized Medicine and Epigenomics Market Size by Type (2022-2027)
9.2.3 Latin America Personalized Medicine and Epigenomics Market Size by Type (2016-2027)
9.3 Latin America Personalized Medicine and Epigenomics Market Size by Application
9.3.1 Latin America Personalized Medicine and Epigenomics Market Size by Application (2016-2021)
9.3.2 Latin America Personalized Medicine and Epigenomics Market Size by Application (2022-2027)
9.3.3 Latin America Personalized Medicine and Epigenomics Market Size by Application (2016-2027)
9.4 Latin America Personalized Medicine and Epigenomics Market Size by Country
9.4.1 Latin America Personalized Medicine and Epigenomics Market Size by Country (2016-2021)
9.4.2 Latin America Personalized Medicine and Epigenomics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Personalized Medicine and Epigenomics Market Size (2016-2027)
10.2 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Type
10.2.1 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Type (2016-2027)
10.3 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Application
10.3.1 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Application (2016-2027)
10.4 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country
10.4.1 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Details
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Personalized Medicine and Epigenomics Introduction
11.1.4 Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.1.5 Abbott Laboratories Recent Development
11.2 Affymetrix
11.2.1 Affymetrix Company Details
11.2.2 Affymetrix Business Overview
11.2.3 Affymetrix Personalized Medicine and Epigenomics Introduction
11.2.4 Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.2.5 Affymetrix Recent Development
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Details
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Personalized Medicine and Epigenomics Introduction
11.3.4 Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.3.5 Agilent Technologies Recent Development
11.4 Astellas Pharmaceuticals
11.4.1 Astellas Pharmaceuticals Company Details
11.4.2 Astellas Pharmaceuticals Business Overview
11.4.3 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Introduction
11.4.4 Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.4.5 Astellas Pharmaceuticals Recent Development
11.5 BAYER AG
11.5.1 BAYER AG Company Details
11.5.2 BAYER AG Business Overview
11.5.3 BAYER AG Personalized Medicine and Epigenomics Introduction
11.5.4 BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.5.5 BAYER AG Recent Development
11.6 Bio Vision
11.6.1 Bio Vision Company Details
11.6.2 Bio Vision Business Overview
11.6.3 Bio Vision Personalized Medicine and Epigenomics Introduction
11.6.4 Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.6.5 Bio Vision Recent Development
11.7 Celgene Corp.
11.7.1 Celgene Corp. Company Details
11.7.2 Celgene Corp. Business Overview
11.7.3 Celgene Corp. Personalized Medicine and Epigenomics Introduction
11.7.4 Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.7.5 Celgene Corp. Recent Development
11.8 Emd Millipore
11.8.1 Emd Millipore Company Details
11.8.2 Emd Millipore Business Overview
11.8.3 Emd Millipore Personalized Medicine and Epigenomics Introduction
11.8.4 Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.8.5 Emd Millipore Recent Development
11.9 Epigenomics AG
11.9.1 Epigenomics AG Company Details
11.9.2 Epigenomics AG Business Overview
11.9.3 Epigenomics AG Personalized Medicine and Epigenomics Introduction
11.9.4 Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.9.5 Epigenomics AG Recent Development
11.10 Epigentex
11.10.1 Epigentex Company Details
11.10.2 Epigentex Business Overview
11.10.3 Epigentex Personalized Medicine and Epigenomics Introduction
11.10.4 Epigentex Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.10.5 Epigentex Recent Development
11.11 Envivo Pharmaceuticals (Forum Pharmaceutricals)
11.11.1 Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Details
11.11.2 Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview
11.11.3 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Introduction
11.11.4 Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.11.5 Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Development
11.12 Gilead Sciences
11.12.1 Gilead Sciences Company Details
11.12.2 Gilead Sciences Business Overview
11.12.3 Gilead Sciences Personalized Medicine and Epigenomics Introduction
11.12.4 Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.12.5 Gilead Sciences Recent Development
11.13 Glaxosmithkline
11.13.1 Glaxosmithkline Company Details
11.13.2 Glaxosmithkline Business Overview
11.13.3 Glaxosmithkline Personalized Medicine and Epigenomics Introduction
11.13.4 Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.13.5 Glaxosmithkline Recent Development
11.14 Illumina Inc.
11.14.1 Illumina Inc. Company Details
11.14.2 Illumina Inc. Business Overview
11.14.3 Illumina Inc. Personalized Medicine and Epigenomics Introduction
11.14.4 Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.14.5 Illumina Inc. Recent Development
11.15 Johnson & Johnson
11.15.1 Johnson & Johnson Company Details
11.15.2 Johnson & Johnson Business Overview
11.15.3 Johnson & Johnson Personalized Medicine and Epigenomics Introduction
11.15.4 Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.15.5 Johnson & Johnson Recent Development
11.16 Karus Therapeutics Limited
11.16.1 Karus Therapeutics Limited Company Details
11.16.2 Karus Therapeutics Limited Business Overview
11.16.3 Karus Therapeutics Limited Personalized Medicine and Epigenomics Introduction
11.16.4 Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.16.5 Karus Therapeutics Limited Recent Development
11.17 Laboratory Corp. Of America Holdings
11.17.1 Laboratory Corp. Of America Holdings Company Details
11.17.2 Laboratory Corp. Of America Holdings Business Overview
11.17.3 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Introduction
11.17.4 Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.17.5 Laboratory Corp. Of America Holdings Recent Development
11.18 LES Laboratoires Servier
11.18.1 LES Laboratoires Servier Company Details
11.18.2 LES Laboratoires Servier Business Overview
11.18.3 LES Laboratoires Servier Personalized Medicine and Epigenomics Introduction
11.18.4 LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.18.5 LES Laboratoires Servier Recent Development
11.18 Merck
11.25.1 Merck Company Details
11.25.2 Merck Business Overview
11.25.3 Merck Personalized Medicine and Epigenomics Introduction
11.25.4 Merck Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.25.5 Merck Recent Development
11.20 Naturewise Biotech & Medicals Corp.
11.20.1 Naturewise Biotech & Medicals Corp. Company Details
11.20.2 Naturewise Biotech & Medicals Corp. Business Overview
11.20.3 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Introduction
11.20.4 Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.20.5 Naturewise Biotech & Medicals Corp. Recent Development
11.21 Novartis Pharma AG
11.21.1 Novartis Pharma AG Company Details
11.21.2 Novartis Pharma AG Business Overview
11.21.3 Novartis Pharma AG Personalized Medicine and Epigenomics Introduction
11.21.4 Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.21.5 Novartis Pharma AG Recent Development
11.22 Oncolys Biopharma Inc.
11.22.1 Oncolys Biopharma Inc. Company Details
11.22.2 Oncolys Biopharma Inc. Business Overview
11.22.3 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Introduction
11.22.4 Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.22.5 Oncolys Biopharma Inc. Recent Development
11.23 Orchid Chemicals & Pharmaceuticals Limited
11.23.1 Orchid Chemicals & Pharmaceuticals Limited Company Details
11.23.2 Orchid Chemicals & Pharmaceuticals Limited Business Overview
11.23.3 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
11.23.4 Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.23.5 Orchid Chemicals & Pharmaceuticals Limited Recent Development
11.24 Progen Pharmaceuticals Limited
11.24.1 Progen Pharmaceuticals Limited Company Details
11.24.2 Progen Pharmaceuticals Limited Business Overview
11.24.3 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
11.24.4 Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.24.5 Progen Pharmaceuticals Limited Recent Development
11.25 Quest Diagnostics
11.25.1 Quest Diagnostics Company Details
11.25.2 Quest Diagnostics Business Overview
11.25.3 Quest Diagnostics Personalized Medicine and Epigenomics Introduction
11.25.4 Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.25.5 Quest Diagnostics Recent Development
11.26 Roche Holding AG
11.26.1 Roche Holding AG Company Details
11.26.2 Roche Holding AG Business Overview
11.26.3 Roche Holding AG Personalized Medicine and Epigenomics Introduction
11.26.4 Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.26.5 Roche Holding AG Recent Development
11.27 Rubicon Genomics
11.27.1 Rubicon Genomics Company Details
11.27.2 Rubicon Genomics Business Overview
11.27.3 Rubicon Genomics Personalized Medicine and Epigenomics Introduction
11.27.4 Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.27.5 Rubicon Genomics Recent Development
11.28 Takeda Pharmaceutical Company Limited
11.28.1 Takeda Pharmaceutical Company Limited Company Details
11.28.2 Takeda Pharmaceutical Company Limited Business Overview
11.28.3 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Introduction
11.28.4 Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
11.28.5 Takeda Pharmaceutical Company Limited Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Personalized Medicine and Epigenomics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Reagents
Table 3. Key Players of Kits
Table 4. Key Players of Instruments
Table 5. Key Players of Enzymes
Table 6. Key Players of Services
Table 7. Global Personalized Medicine and Epigenomics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Personalized Medicine and Epigenomics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Personalized Medicine and Epigenomics Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Personalized Medicine and Epigenomics Market Share by Regions (2016-2021)
Table 11. Global Personalized Medicine and Epigenomics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Personalized Medicine and Epigenomics Market Share by Regions (2022-2027)
Table 13. Personalized Medicine and Epigenomics Market Trends
Table 14. Personalized Medicine and Epigenomics Market Drivers
Table 15. Personalized Medicine and Epigenomics Market Challenges
Table 16. Personalized Medicine and Epigenomics Market Restraints
Table 17. Global Personalized Medicine and Epigenomics Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Personalized Medicine and Epigenomics Market Share by Players (2016-2021)
Table 19. Global Top Personalized Medicine and Epigenomics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Personalized Medicine and Epigenomics as of 2020)
Table 20. Ranking of Global Top Personalized Medicine and Epigenomics Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Personalized Medicine and Epigenomics Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Personalized Medicine and Epigenomics Product Solution and Service
Table 24. Date of Enter into Personalized Medicine and Epigenomics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Personalized Medicine and Epigenomics Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Personalized Medicine and Epigenomics Revenue Market Share by Type (2016-2021)
Table 28. Global Personalized Medicine and Epigenomics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Personalized Medicine and Epigenomics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Personalized Medicine and Epigenomics Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Personalized Medicine and Epigenomics Revenue Market Share by Application (2016-2021)
Table 32. Global Personalized Medicine and Epigenomics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Personalized Medicine and Epigenomics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Personalized Medicine and Epigenomics Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Personalized Medicine and Epigenomics Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Personalized Medicine and Epigenomics Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Personalized Medicine and Epigenomics Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Personalized Medicine and Epigenomics Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Personalized Medicine and Epigenomics Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Personalized Medicine and Epigenomics Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Personalized Medicine and Epigenomics Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Personalized Medicine and Epigenomics Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Personalized Medicine and Epigenomics Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Personalized Medicine and Epigenomics Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Personalized Medicine and Epigenomics Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Personalized Medicine and Epigenomics Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Personalized Medicine and Epigenomics Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Personalized Medicine and Epigenomics Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Personalized Medicine and Epigenomics Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Personalized Medicine and Epigenomics Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Personalized Medicine and Epigenomics Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Personalized Medicine and Epigenomics Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Personalized Medicine and Epigenomics Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Personalized Medicine and Epigenomics Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Personalized Medicine and Epigenomics Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Personalized Medicine and Epigenomics Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Personalized Medicine and Epigenomics Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Personalized Medicine and Epigenomics Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Personalized Medicine and Epigenomics Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2022-2027) & (US$ Million)
Table 64. Abbott Laboratories Company Details
Table 65. Abbott Laboratories Business Overview
Table 66. Abbott Laboratories Personalized Medicine and Epigenomics Product
Table 67. Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 68. Abbott Laboratories Recent Development
Table 69. Affymetrix Company Details
Table 70. Affymetrix Business Overview
Table 71. Affymetrix Personalized Medicine and Epigenomics Product
Table 72. Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 73. Affymetrix Recent Development
Table 74. Agilent Technologies Company Details
Table 75. Agilent Technologies Business Overview
Table 76. Agilent Technologies Personalized Medicine and Epigenomics Product
Table 77. Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 78. Agilent Technologies Recent Development
Table 79. Astellas Pharmaceuticals Company Details
Table 80. Astellas Pharmaceuticals Business Overview
Table 81. Astellas Pharmaceuticals Personalized Medicine and Epigenomics Product
Table 82. Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 83. Astellas Pharmaceuticals Recent Development
Table 84. BAYER AG Company Details
Table 85. BAYER AG Business Overview
Table 86. BAYER AG Personalized Medicine and Epigenomics Product
Table 87. BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 88. BAYER AG Recent Development
Table 89. Bio Vision Company Details
Table 90. Bio Vision Business Overview
Table 91. Bio Vision Personalized Medicine and Epigenomics Product
Table 92. Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 93. Bio Vision Recent Development
Table 94. Celgene Corp. Company Details
Table 95. Celgene Corp. Business Overview
Table 96. Celgene Corp. Personalized Medicine and Epigenomics Product
Table 97. Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 98. Celgene Corp. Recent Development
Table 99. Emd Millipore Company Details
Table 100. Emd Millipore Business Overview
Table 101. Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 102. Emd Millipore Recent Development
Table 103. Epigenomics AG Company Details
Table 104. Epigenomics AG Business Overview
Table 105. Epigenomics AG Personalized Medicine and Epigenomics Product
Table 106. Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 107. Epigenomics AG Recent Development
Table 108. Epigentex Company Details
Table 109. Epigentex Business Overview
Table 110. Epigentex Personalized Medicine and Epigenomics Product
Table 111. Epigentex Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 112. Epigentex Recent Development
Table 113. Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Details
Table 114. Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview
Table 115. Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Product
Table 116. Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 117. Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Development
Table 118. Gilead Sciences Company Details
Table 119. Gilead Sciences Business Overview
Table 120. Gilead Sciences Personalized Medicine and Epigenomics Product
Table 121. Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 122. Gilead Sciences Recent Development
Table 123. Glaxosmithkline Company Details
Table 124. Glaxosmithkline Business Overview
Table 125. Glaxosmithkline Personalized Medicine and Epigenomics Product
Table 126. Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 127. Glaxosmithkline Recent Development
Table 128. Illumina Inc. Company Details
Table 129. Illumina Inc. Business Overview
Table 130. Illumina Inc. Personalized Medicine and Epigenomics Product
Table 131. Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 132. Illumina Inc. Recent Development
Table 133. Johnson & Johnson Company Details
Table 134. Johnson & Johnson Business Overview
Table 135. Johnson & Johnson Personalized Medicine and Epigenomics Product
Table 136. Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 137. Johnson & Johnson Recent Development
Table 138. Karus Therapeutics Limited Company Details
Table 139. Karus Therapeutics Limited Business Overview
Table 140. Karus Therapeutics Limited Personalized Medicine and Epigenomics Product
Table 141. Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 142. Karus Therapeutics Limited Recent Development
Table 143. Laboratory Corp. Of America Holdings Company Details
Table 144. Laboratory Corp. Of America Holdings Business Overview
Table 145. Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Product
Table 146. Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 147. Laboratory Corp. Of America Holdings Recent Development
Table 148. LES Laboratoires Servier Company Details
Table 149. LES Laboratoires Servier Business Overview
Table 150. LES Laboratoires Servier Personalized Medicine and Epigenomics Product
Table 151. LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 152. LES Laboratoires Servier Recent Development
Table 153. Merck Company Details
Table 154. Merck Business Overview
Table 155. Merck Personalized Medicine and Epigenomics Product
Table 156. Merck Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 157. Merck Recent Development
Table 158. Naturewise Biotech & Medicals Corp. Company Details
Table 159. Naturewise Biotech & Medicals Corp. Business Overview
Table 160. Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Product
Table 161. Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 162. Naturewise Biotech & Medicals Corp. Recent Development
Table 163. Novartis Pharma AG Company Details
Table 164. Novartis Pharma AG Business Overview
Table 165. Novartis Pharma AG Personalized Medicine and Epigenomics Product
Table 166. Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 167. Novartis Pharma AG Recent Development
Table 168. Oncolys Biopharma Inc. Company Details
Table 169. Oncolys Biopharma Inc. Business Overview
Table 170. Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Product
Table 171. Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 172. Oncolys Biopharma Inc. Recent Development
Table 173. Orchid Chemicals & Pharmaceuticals Limited Company Details
Table 174. Orchid Chemicals & Pharmaceuticals Limited Business Overview
Table 175. Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Product
Table 176. Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 177. Orchid Chemicals & Pharmaceuticals Limited Recent Development
Table 178. Progen Pharmaceuticals Limited Company Details
Table 179. Progen Pharmaceuticals Limited Business Overview
Table 180. Progen Pharmaceuticals Limited Personalized Medicine and EpigenomicsProduct
Table 181. Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 182. Progen Pharmaceuticals Limited Recent Development
Table 183. Quest Diagnostics Company Details
Table 184. Quest Diagnostics Business Overview
Table 185. Quest Diagnostics Personalized Medicine and Epigenomics Product
Table 186. Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 187. Quest Diagnostics Recent Development
Table 188. Roche Holding AG Company Details
Table 189. Roche Holding AG Business Overview
Table 190. Roche Holding AG Personalized Medicine and Epigenomics Product
Table 191. Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 192. Roche Holding AG Recent Development
Table 193. Rubicon Genomics Company Details
Table 194. Rubicon Genomics Business Overview
Table 195. Rubicon Genomics Personalized Medicine and Epigenomics Product
Table 196. Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 197. Rubicon Genomics Recent Development
Table 198. Takeda Pharmaceutical Company Limited Company Details
Table 199. Takeda Pharmaceutical Company Limited Business Overview
Table 200. Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Product
Table 201. Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
Table 202. Takeda Pharmaceutical Company Limited Recent Development
Table 203. Research Programs/Design for This Report
Table 204. Key Data Information from Secondary Sources
Table 205. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Personalized Medicine and Epigenomics Market Share by Type: 2020 VS 2027
Figure 2. Reagents Features
Figure 3. Kits Features
Figure 4. Instruments Features
Figure 5. Enzymes Features
Figure 6. Services Features
Figure 7. Global Personalized Medicine and Epigenomics Market Share by Application: 2020 VS 2027
Figure 8. Oncology Case Studies
Figure 9. Non-Oncology Case Studies
Figure 10. Cancer Drug Technology Case Studies
Figure 11. Personalized Medicine and Epigenomics Report Years Considered
Figure 12. Global Personalized Medicine and Epigenomics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Personalized Medicine and Epigenomics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Personalized Medicine and Epigenomics Market Share by Regions: 2020 VS 2027
Figure 15. Global Personalized Medicine and Epigenomics Market Share by Regions (2022-2027)
Figure 16. Global Personalized Medicine and Epigenomics Market Share by Players in 2020
Figure 17. Global Top Personalized Medicine and Epigenomics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Personalized Medicine and Epigenomics as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Personalized Medicine and Epigenomics Revenue in 2020
Figure 19. Global Personalized Medicine and Epigenomics Revenue Market Share by Type (2016-2021)
Figure 20. Global Personalized Medicine and Epigenomics Revenue Market Share by Type (2022-2027)
Figure 21. North America Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Personalized Medicine and Epigenomics Market Share by Type (2016-2027)
Figure 23. North America Personalized Medicine and Epigenomics Market Share by Application (2016-2027)
Figure 24. North America Personalized Medicine and Epigenomics Market Share by Country (2016-2027)
Figure 25. United States Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Personalized Medicine and Epigenomics Market Share by Type (2016-2027)
Figure 29. Europe Personalized Medicine and Epigenomics Market Share by Application (2016-2027)
Figure 30. Europe Personalized Medicine and Epigenomics Market Share by Country (2016-2027)
Figure 31. Germany Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Personalized Medicine and Epigenomics Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Personalized Medicine and Epigenomics Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Personalized Medicine and Epigenomics Market Share by Region (2016-2027)
Figure 41. China Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Personalized Medicine and Epigenomics Market Share by Type (2016-2027)
Figure 49. Latin America Personalized Medicine and Epigenomics Market Share by Application (2016-2027)
Figure 50. Latin America Personalized Medicine and Epigenomics Market Share by Country (2016-2027)
Figure 51. Mexico Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Personalized Medicine and Epigenomics Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Personalized Medicine and Epigenomics Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Personalized Medicine and Epigenomics Market Share by Country (2016-2027)
Figure 57. Turkey Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Abbott Laboratories Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 61. Affymetrix Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 62. Agilent Technologies Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 63. Astellas Pharmaceuticals Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 64. BAYER AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 65. Bio Vision Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 66. Celgene Corp. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 67. Emd Millipore Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 68. Epigenomics AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 69. Epigentex Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 70. Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 71. Gilead Sciences Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 72. Glaxosmithkline Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 73. Illumina Inc. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 74. Johnson & Johnson Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 75. Karus Therapeutics Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 76. Laboratory Corp. Of America Holdings Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 77. LES Laboratoires Servier Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 78. Merck Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 79. Naturewise Biotech & Medicals Corp. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 80. Novartis Pharma AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 81. Oncolys Biopharma Inc. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 82. Orchid Chemicals & Pharmaceuticals Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 83. Progen Pharmaceuticals Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 84. Quest Diagnostics Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 85. Roche Holding AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 86. Rubicon Genomics Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 87. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed
世界の個別化がん医療市場規模・現状・予測（2021年-2027年） Personalized medicine is at an early stage of development. Scientists found that some cancer cells have particular proteins in the cell and others don’t. Sometimes, cancer cells have far more of a particular protein than healthy cells. Genetic testing of cancer cells and normal cells helps doctors c…- 世界の個別化がんワクチン市場規模・現状・予測（2021年-2027年） Personalized Cancer Vaccines are the type of immunotherapy that boosts the immune system to fight against a cancerous cell. These types of vaccine are tailored to match a patient’s particular tumor cell after received cancer related surgery. This vaccine may prevent from cancer, destroy cancer cells…
- 世界の個別化医療におけるナノ材料市場規模・現状・予測（2021年-2027年） The use of nanotechnology offers new opportunities for the development of novel strategies in terms of prevention, diagnosis, and treatment viral infections. Market Analysis and Insights: Global Nanomaterials in Personalized Medicine Market The global Nanomaterials in Personalized Medicine market si…
- 世界の腫瘍個別化医療市場規模・現状・予測（2021年-2027年） Oncology is a type of medicine that refers to the diagnosis, treatment and prevention of different types of cancers like blood cancer, skin cancer, breast cancer, lung cancer and others. Market Analysis and Insights: Global Personalized Medicines In Oncology Market The global Personalized Medicines …
- 世界の分子生物酵素＆キット＆試薬市場規模・現状・予測（2021年-2027年） Enzymes are macromolecular biological catalysts that accelerate chemical reactions. Molecular biology enzymes, kits, and reagents are extensively used in biotechnology and pharma sector for creating consumables necessary for molecular biology research. Pharmaceutical companies also use protein and r…